Inside VIVEbiotech’s Work with Zelluna on TCR-NK Cell Therapy - Top-Institutions - MDSpire

Inside VIVEbiotech’s Work with Zelluna on TCR-NK Cell Therapy

VIVEbiotech CEO Jon Alberdi lifts the lid on an eight-year collaboration focused on GMP lentiviral vectors for off-the-shelf solid tumor therapies

  • July 14, 2026

  • 4 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Cell Therapy

  • #2

    Masonic Cancer Center, University of Minnesota
    Masonic Cancer Center, University of Minnesota

    Minneapolis, Minnesota

    Key Differentiators

    • Oncology
    • NK Cell Therapy

  • #3

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology
    • CAR-T Therapy

Original Source(s)

Inside VIVEbiotech’s Work with Zelluna on TCR-NK Cell Therapy

  • July 14, 2026

Related Content

Papulopustular eruptions associated with EGFR-pathway-related targeted therapies: clinical spectrum, evidence boundaries, folliculocentric inflammation, and management considerations

Editorial: Molecular pathways and signaling molecules in cancer therapy: advances and innovations

Intestinal metastases diffused from primary gastric adenocarcinoma with signet ring cells: case report